Hims & Hers Health (NYSE:HIMS) Announces Earnings Results, Beats Estimates By $0.02 EPS

Hims & Hers Health (NYSE:HIMS) announced its quarterly earnings data on Monday. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.02, Zacks reports. The company had revenue of $481.14 million during the quarter, compared to analysts’ expectations of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. Hims & Hers Health updated its Q1 2025 guidance to EPS and its FY 2025 guidance to EPS.

Hims & Hers Health Trading Up 10.8 %

Hims & Hers Health stock traded up $4.30 during midday trading on Wednesday, reaching $44.16. 7,604,670 shares of the stock traded hands, compared to its average volume of 20,639,279. The firm has a market cap of $9.65 billion, a PE ratio of 99.45 and a beta of 1.35. The company has a 50-day simple moving average of $35.62 and a two-hundred day simple moving average of $26.25. Hims & Hers Health has a 12-month low of $11.20 and a 12-month high of $72.98.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the company. Citigroup upped their price target on Hims & Hers Health from $25.00 to $27.00 and gave the company a “sell” rating in a research report on Tuesday. Needham & Company LLC upped their target price on Hims & Hers Health from $31.00 to $61.00 and gave the company a “buy” rating in a report on Tuesday. TD Cowen reiterated a “buy” rating and set a $28.00 price target on shares of Hims & Hers Health in a report on Wednesday, November 20th. BTIG Research initiated coverage on shares of Hims & Hers Health in a research report on Tuesday, January 7th. They set a “buy” rating and a $35.00 price target on the stock. Finally, Truist Financial raised their price objective on shares of Hims & Hers Health from $24.00 to $39.00 and gave the stock a “hold” rating in a research report on Wednesday. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $34.47.

Insiders Place Their Bets

In other Hims & Hers Health news, CEO Andrew Dudum sold 33,513 shares of the business’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $33.38, for a total value of $1,118,663.94. Following the completion of the transaction, the chief executive officer now owns 33,502 shares in the company, valued at $1,118,296.76. The trade was a 50.01 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Michael Chi sold 17,303 shares of the stock in a transaction on Monday, February 24th. The shares were sold at an average price of $48.14, for a total value of $832,966.42. Following the completion of the sale, the insider now owns 193,601 shares in the company, valued at approximately $9,319,952.14. The trade was a 8.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,097,578 shares of company stock worth $38,080,320 over the last three months. Company insiders own 17.71% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.